Interaction of [³H]dipyridamole with the nucleoside transporters of human erythrocytes and cultured animal cells

Summary

Equilibrium binding of [³H]dipyridamole identified high-affinity (K _i ∼10nm) binding sites on human erythrocytes (∼5×10⁵ sites/cell) and on HeLa cells (∼5×10⁶ sites/cell). The equilibration of dipyridamole with these sites on human erythrocytes was compatible with a second-order process which proceeded at 22°C with a rate constant of about 6×10⁶ m ⁻¹ sec⁻¹. Binding of dipyridamole to these sites correlated kinetically with the inhibition of the equilibrium exchange of 500 μm uridine in these cells and was inhibited in a concentration-dependent manner by nucleosides and other inhibitors of nucleoside transport, such as nitrobenzylthioinosine, dilazep and lidoflazine, but not by hypoxanthine, which is not a substrate for the nucleoside transporter of human erythrocytes. The results indicate that the substrate binding site of the transporter is part of the high-affinity dipyridamole binding site. Bound [³H]dipyridamole became displaced from these sites on human erythrocytes by incubation with an excess of unlabeled dipyridamole or high concentrations of nucleosides and inhibitors of nucleoside transport, but neither by hypoxanthine nor sugars. Dissociation of [³H]dipyridamole behaved as a simple first-order process, but the rate constant was about one order of magnitude lower (about 3×10⁻³ sec⁻¹) than anticipated for typical ligand-protein binding on the basis of the measured association rate and equilibrium constants. The reason for this discrepancy has not been resolved. No high-affinity dipyridamole binding sites were detected on Novikoff rat hepatoma cells, P388, L1210 and S49 mouse leukemia cells or Chinese hamster ovary cells, and their absence correlated with a greater resistance of nucleoside transport in these cells to inhibition by dipyridamole. All cells expressed considerable low affinity (K _d>0.5 μm) and nonspecific binding of dipyridamole.